A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS or PMS

Neurology
Michael Sy
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)
Multiple Sclerosis MS

Study Description

The study will consist of 2 parts: a dose escalation (Part A) and a dose expansion (Part B).

The dose escalation (Part A) will evaluate the safety, tolerability, and pharmacokinetics of

increasing doses of CC-97540 in a single administration to establish the RP2D for dose

expansion. The dose expansion (Part B) will further evaluate the safety,

PK/pharmacodynamics (Pd), and preliminary efficacy of CC-97540 at the RP2D(s). One or

more doses may be chosen as preliminary RP2D(s) for further evaluation in Part B. A Phase

2 study expansion cohort may be initiated upon evaluation of available safety, PK,

pharmacodynamic, and preliminary efficacy data from the dose escalation and dose expansion

portions of this study. The Phase 2 study expansion cohort would be introduced via a protocol

amendment once appropriate supportive data have been generated. The time on study will be

composed of 3 periods: Pre-treatment, Treatment, and Post-treatment Follow-up.

Eligibility

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.